

Antengene establishes new drug discovery centre in Shanghai

13 October 2020 | News

Dedicated to the Research and Development of Innovative Therapies for Cancer



Antengene Corporation, a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapies in oncology and hematology, has announced the official opening of the Antengene's New Drug Discovery Center based in Zhangjiang, Shanghai.

As a leading clinical-stage Asia-Pacific biopharmaceutical company focused on innovative oncology medicines, Antengene aims to extend patients' lives and improve their quality of life, through new drug discovery, development, and dedicating itself to providing innovative anti-cancer therapies for patients in China, Asia-Pacific and around the world.

Shanghai Zhangjiang Hi-Tech Park is a highlight in the history of Pudong's reform and development. R&D resources are highly concentrated, and innovative achievements are rapidly emerging. With its continuously influx of talented scientists and industry professionals and technology platform advantages, it is leading the development of China's biomedical industry.

Antengene's New Drug Discovery Center, established in Zhangjiang, Shanghai, will build a platform for targeted-based screening and lead drug discovery by capitalizing on the talented scientists and technical advantages of "Chinese Pharma Valley", and focus on potential first-in-class or best-in-class innovative anti-cancer drugs based on complete upstream and downstream industrial chains of the park.

At present, the Drug Discovery Center is equipped with a small molecule formulation R&D laboratory, an antibody discovery laboratory, cell culture chambers, and has introduced state-of-art devices such as spectral flow cytometry, automatic protein purification system and high-resolution fluorescence microscope.